Neurodegenerative
Disease Management
A clinical approach to diagnosing and managing Alzheimer's, Parkinson's, and related disorders in the outpatient and longitudinal setting.
What Is Neurodegeneration?
Neurodegenerative diseases are characterized by the progressive loss of structure or function of neurons, often driven by abnormal protein aggregation. They are chronic, irreversible, and progressive.
Key Players
Disease Progression Curve
Core Rule: Alzheimer's Pharmacotherapy
Core Rule: Parkinson's Pharmacotherapy
Treatment is symptomatic and centered on restoring dopaminergic tone. The relationship between symptom severity and drug choice can be modeled as a threshold-driven escalation:
Distinguishing AD vs PD Dementia
| Alzheimer's | Parkinson / Lewy Body | |
|---|---|---|
| Early feature | Memory loss | Motor symptoms / visual hallucinations |
| Cognition timing | Cognitive first | Motor first (PDD), or concurrent (DLB) |
| Antipsychotic risk | Moderate | Severe sensitivity |
| First-line drug | Cholinesterase inhibitor | Levodopa / dopamine agonist |
How to Apply It
Worked Example: Early AD
A 72-year-old woman has 18 months of progressive short-term memory loss. MMSE is 22/30. Labs and MRI exclude reversible causes.
Worked Example: Advancing PD
A 78-year-old man with Parkinson's has worsening bradykinesia limiting his independence. He already takes a low-dose dopamine agonist.
Worked Example: Behavioral Crisis
A patient with Lewy body dementia develops agitation and visual hallucinations. The nursing facility requests an antipsychotic.
Common Mistakes
Management Summary
| Scenario | First-Line | Add / Avoid |
|---|---|---|
| Mild-mod AD | Cholinesterase inhibitor | Add memantine if severe |
| Severe AD | ChEI + memantine | Maximize support |
| Young / mild PD | Dopamine agonist / MAO-B | Delay levodopa |
| Older / disabling PD | Levodopa-carbidopa | Watch dyskinesia |
| Lewy body + agitation | Treat triggers, ChEI | Avoid typicals |
Check Your Understanding
Question 1 of 5
A 70-year-old man with newly diagnosed mild Alzheimer's disease (MMSE 24) and no comorbidities should be started on which agent?
Question 2 of 5
An 80-year-old woman with Parkinson's disease has disabling bradykinesia despite a dopamine agonist. What is the most effective next step?
Question 3 of 5
In a patient with Lewy body dementia and agitation, which medication is most dangerous and should be avoided?
Question 4 of 5
Before starting therapy for a patient with suspected dementia, which step is essential?
Question 5 of 5
A patient with moderate-to-severe Alzheimer's on donepezil continues to decline. What is the most appropriate addition?